spironolactone has been researched along with Fatty Liver, Nonalcoholic in 6 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The beneficial effects of mineralocorticoid receptor blockade by spironolactone have been shown in animal models of non-alcoholic fatty liver disease (NAFLD)." | 9.24 | Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. ( Katsinelos, P; Kountouras, J; Mantzoros, CS; Polymerou, V; Polyzos, SA, 2017) |
| "Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans." | 7.79 | Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. ( Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD) was recently renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) to better characterize its pathogenic origin." | 5.91 | Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. ( Chatzimichael, E; Deretzi, G; Doulberis, M; Exadaktylos, AK; Gelasakis, A; Gialamprinou, D; Karafyllidou, K; Kotronis, G; Kountouras, J; Papaefthymiou, A; Papamichos, SI; Polyzos, SA; Sampsonas, F; Vardaka, E, 2023) |
| "The beneficial effects of mineralocorticoid receptor blockade by spironolactone have been shown in animal models of non-alcoholic fatty liver disease (NAFLD)." | 5.24 | Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. ( Katsinelos, P; Kountouras, J; Mantzoros, CS; Polymerou, V; Polyzos, SA, 2017) |
| "Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans." | 3.79 | Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. ( Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T, 2013) |
| "In the randomized controlled trial, NAFLD patients were assigned to vitamin E (400 IU/d) or spironolactone (25 mg/d) plus vitamin E for 52 weeks." | 2.87 | Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. ( Anastasilakis, AD; Doulberis, M; Hawa, G; Katsinelos, P; Kountouras, J; Makras, P; Missbichler, A; Polyzos, SA; Sonnleitner, L; Terpos, E, 2018) |
| "Nonalcoholic fatty liver disease (NAFLD) was recently renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) to better characterize its pathogenic origin." | 1.91 | Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. ( Chatzimichael, E; Deretzi, G; Doulberis, M; Exadaktylos, AK; Gelasakis, A; Gialamprinou, D; Karafyllidou, K; Kotronis, G; Kountouras, J; Papaefthymiou, A; Papamichos, SI; Polyzos, SA; Sampsonas, F; Vardaka, E, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Papaefthymiou, A | 1 |
| Doulberis, M | 2 |
| Karafyllidou, K | 1 |
| Chatzimichael, E | 1 |
| Deretzi, G | 2 |
| Exadaktylos, AK | 1 |
| Sampsonas, F | 1 |
| Gelasakis, A | 1 |
| Papamichos, SI | 1 |
| Kotronis, G | 1 |
| Gialamprinou, D | 1 |
| Vardaka, E | 1 |
| Polyzos, SA | 4 |
| Kountouras, J | 4 |
| Mantzoros, CS | 1 |
| Polymerou, V | 1 |
| Katsinelos, P | 2 |
| Anastasilakis, AD | 1 |
| Makras, P | 1 |
| Hawa, G | 1 |
| Sonnleitner, L | 1 |
| Missbichler, A | 1 |
| Terpos, E | 1 |
| Wada, T | 1 |
| Miyashita, Y | 1 |
| Sasaki, M | 1 |
| Aruga, Y | 1 |
| Nakamura, Y | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Kanasaki, K | 1 |
| Kitada, M | 1 |
| Koya, D | 1 |
| Shimano, H | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Pizarro, M | 1 |
| Solís, N | 1 |
| Quintero, P | 1 |
| Barrera, F | 1 |
| Cabrera, D | 1 |
| Rojas-de Santiago, P | 1 |
| Arab, JP | 1 |
| Padilla, O | 1 |
| Roa, JC | 1 |
| Moshage, H | 1 |
| Wree, A | 1 |
| Inzaugarat, E | 1 |
| Feldstein, AE | 1 |
| Fardella, CE | 1 |
| Baudrand, R | 1 |
| Riquelme, A | 1 |
| Arrese, M | 1 |
| Zafeiriadou, E | 1 |
| Patsiaoura, K | 1 |
| Katsiki, E | 1 |
| Zavos, C | 1 |
| Tsarouchas, G | 1 |
| Rakitzi, P | 1 |
| Slavakis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study[NCT01147523] | Phase 2 | 30 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for spironolactone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
Topics: Adipokines; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Combined Modality Th | 2017 |
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.
Topics: Carrier Proteins; Case-Control Studies; Drug Therapy, Combination; Humans; Mineralocorticoid Recepto | 2018 |
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Female; Humans; Insulin Resistance; Male; Mice; Middle Aged; Mineralocorticoid | 2011 |
3 other studies available for spironolactone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.
Topics: Humans; Mineralocorticoid Receptor Antagonists; Non-alcoholic Fatty Liver Disease; Renin-Angiotensin | 2023 |
Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.
Topics: Animals; Cells, Cultured; Diet, High-Fat; Dietary Carbohydrates; Eplerenone; Fatty Liver; Fructose; | 2013 |
Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Topics: Animals; Biomarkers; Disease Models, Animal; Eplerenone; Liver; Liver Cirrhosis; Male; Mice; Mice, I | 2015 |